PMDA — authorised 28 March 2016
- Marketing authorisation holder: GlaxoSmithKline K.K.
- Status: approved
PMDA authorised Nucala on 28 March 2016
Same drug, different regulators. Each page below lists the local marketing authorisation, HTA position, pricing, and adverse-event data.
Yes. PMDA authorised it on 28 March 2016.
GlaxoSmithKline K.K. holds the Japanese marketing authorisation.